Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics

This randomized, double-blind, parallel group, placebo-controlled study will evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks for 3 doses on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.

Approximately 38 non-smoking men and women (18 - 65 years of age) corticosteroid-free (oral and inhaled) mild, atopic asthmatics who have demonstrated a dual (early and late) asthmatic response to inhaled allergen challenge at screening will be recruited to complete the study.

Inclusion criteria

• Provision of informed consent prior to any study specific procedures
• Female or male aged 18 to 65 years, inclusively, at the time of enrolment.
• General good health
• Mild, stable, allergic asthma and asthma therapy limited to inhaled, short-acting beta 2 agonists (not more than twice weekly)
• Positive skin-prick test to at least one common aeroallergen

Exclusion criteria

• Current lung disease other than mild allergic asthma
• Any history or symptoms of disease, including, but not limited to, cardiovascular, neurologic, autoimmune or haematologic
• Any clinically significant abnormal findings in laboratory test results in complete blood count, coagulation, chemistry panel and urinalysis at enrolment and during screening period
• History of anaphylaxis to any biologic therapy or vaccine